Kandoset

Amlodipine and Candesartan Cilexetil, the active ingredient in Kandoset, is a calcium channel blocker and angiotensin II receptor blocker presented as a tablet for oral use. It lowers blood pressure in adults with hypertension, providing combined vasodilatory and renin‑angiotensin system inhibition.

GNH USA supplies Kandoset as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Our network ensures timely delivery and regulatory compliance across EU and other markets.

Kandoset, a fixed‑dose combination antihypertensive, is indicated for conditions involving elevated arterial pressure.

- Hypertension: achieves sustained reduction of systolic and diastolic blood pressure in adults. - Essential hypertension: provides additive blood pressure control when monotherapy is insufficient. - Primary hypertension: helps patients reach target blood pressure levels recommended by clinical guidelines.

Common Side Effects: - Peripheral edema: swelling of the ankles or feet. - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Dizziness or light‑headedness, especially after standing. - Fatigue: feeling unusually tired. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat that may impair breathing. - Severe hypotension: marked drop in blood pressure causing fainting. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Hyperkalemia: high potassium levels that can affect heart rhythm. - Renal impairment: worsening kidney function, especially in patients with pre‑existing disease. - Myocardial infarction: rare reports of heart attack in susceptible individuals.

Patients should be evaluated for cardiovascular and renal status before initiating therapy.

- Blood pressure monitoring: check regularly to avoid excessive hypotension. - Renal function assessment: evaluate serum creatinine and eGFR, especially in the elderly. - Electrolyte surveillance: monitor potassium levels when combined with potassium‑sparing agents. - Hepatic impairment: use with caution in patients with moderate to severe liver disease. - Pregnancy and lactation: discuss risks with a healthcare professional before use. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Drug interactions may alter the efficacy or safety of Kandoset and should be reviewed by a prescriber.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase amlodipine exposure. - Aliskiren in diabetic patients: heightened risk of renal impairment and hyperkalemia. - Concurrent use of other ARBs or ACE inhibitors: may cause additive hypotensive effects and hyperkalemia.

Moderate Interactions (Monitor Closely): - Simvastatin >20 mg: increased risk of myopathy when combined with amlodipine. - Lithium: potential for increased lithium levels and toxicity. - NSAIDs: may reduce antihypertensive effect and affect renal function.